VIEW ALL RESEARCH-GROUP

Metabolism and cancer
Menendez’s Lab

DESCRIPTION

Unlocking the metabolic secrets of cancer: Our “Metabolism and Cancer” team studies how cellular metabolism drives cancer growth, drug resistance, and metastasis. We use cutting-edge laboratory experiments, computational tools and clinical trials to validate our discoveries in cancer patients.

MAIN RESEARCH LINES

  1. CANCER METABOLISM

    Metabolic inhibitors for cancer therapy

    • Metabolic mechanisms of tumorigenesis & drug resistance
    • Clinical development of anti-cancer metabolic drugs

    Mitochondria, senescence, and cancer

    • Mitochondria-based elimination of tumor-/metastasis-initiating cells
    • Metabolic therapy-induced senescence (MTIS)

    Metabolo-immunotherapy

    • Tumor cell-intrinsic immunometabolism 
    • Metabolic/dietary interventions and immunotherapy 
  2. BIOCOMPOUNDS
    • Natural biocompounds for cancer treatment
  3. COMPUTATIONAL BIOLOGY & CHEMISTRY
    • Mathematical modeling of cancer
    • Computational design of anti-cancer metabolic drugs

Javier A. Menendez

Group leaders

IP

Elisabet Cuyàs

Researchers

Established researcher (Miguel Servet)

Eila Serrano Hervás

Researchers

Postdoctoral researcher (INVESTIGO)

Sara Verdura

Researchers

Predoctoral researcher

Àngela Llop Hernández

Young investigators

Predoctoral researcher

Júlia López

Young investigators

Predoctoral researcher

Begoña Martín Castillo

Researchers

Established researcher (Unit of Clinical Research, ICO-Girona)

Eugeni López Bonet

Researchers

Established researcher (Hospital Trueta)

Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets

/in /by

Food Chem Toxicol. 2019 Sep;131:110529. doi: 10.1016/j.fct.2019.05.037. Epub 2019 May 29. ABSTRACT The health promoting effects of extra virgin olive oil (EVOO) relate to its unique repertoire of phenolic compounds. Here, we used a chemoinformatics approach to computationally identify endogenous ligands and assign putative biomolecular targets to oleacein, one of the most abundant secoiridoids in […]

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

/in /by

Aging (Albany NY). 2019 May 9;11(9):2874-2888. doi: 10.18632/aging.101960. ABSTRACT Certain dietary interventions might improve the therapeutic index of cancer treatments. An alternative to the “drug plus diet” approach is the pharmacological reproduction of the metabolic traits of such diets. Here we explored the impact of adding metformin to an established therapeutic regimen on the systemic […]

Stratification of cancer and diabetes based on circulating levels of formate and glucose

/in /by

Cancer Metab. 2019 Apr 24;7:3. doi: 10.1186/s40170-019-0195-x. eCollection 2019. ABSTRACT BACKGROUND: Serum and urine metabolites have been investigated for their use as cancer biomarkers. The specificity of candidate metabolites can be limited by the impact of other disorders on metabolite levels. In particular, the increasing incidence of obesity could become a significant confounding factor. METHODS: […]

A multiscale model of epigenetic heterogeneity-driven cell fate decision-making

/in /by

PLoS Comput Biol. 2019 Apr 30;15(4):e1006592. doi: 10.1371/journal.pcbi.1006592. eCollection 2019 Apr. ABSTRACT The inherent capacity of somatic cells to switch their phenotypic status in response to damage stimuli in vivo might have a pivotal role in ageing and cancer. However, how the entry-exit mechanisms of phenotype reprogramming are established remains poorly understood. In an attempt […]

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin

/in /by

Front Oncol. 2019 Mar 28;9:193. doi: 10.3389/fonc.2019.00193. eCollection 2019. ABSTRACT Background: The minor allele (C) of the single-nucleotide polymorphism (SNP) rs11212617, located near the ataxia telangiectasia mutated (ATM) gene, has been associated with an increased likelihood of treatment success with metformin in type 2 diabetes. We herein investigated whether the same SNP would predict clinical […]

Ruth Lupu | Mayo Clinic, Rochester, USA

Pilar Blancafort | Harry Perkins Institute of Medical Research, Perth, Australia

Francesca Cutruzzolà | Sapienza University, Rome, Italy

Tomás Alarcón | ICREA-Centre de Recerca Matemàtica (CRM), Reus, Spain

Sílvia Osuna | ICREA-Institut de Química Computacional i Catàlisi (IQCC), Girona, Spain

Josep Sardanyés | Centre de Recerca Matemàtica (CRM), Barcelona, Spain

José Antonio Encinar | Universidad Miguel Hernández, Elche, Spain

Vicente Micol | Universidad Miguel Hernández, Elche, Spain

Antonio Segura-Carretero | Universidad de Granada, Granada, Spain

Jorge Joven | Institut d’Investigació Sanitària Pere Virgili (IISPV), Reus, Spain

Carlos Peña Garay | Laboratorio Subterráneo de Canfranc (LSC), Spain

Menendez grup. Research group photo
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

Pujana’s LabPujana's LabGrup-Hematoligia-webSureda’s & Farre’s Lab